Medical Instrument bigshots — Abiomed Inc. ABMDand STERIS plc STE— are pitted against each other in the prospective U.S. MedTech space, which is estimated to reach $343 billion by 2021 at a CAGR of 4.6% (per Lucintel). Notably, these companies benefit from R&D innovation, increasing consolidation and the recent tax abatement.
Medical Instrument Stocks Head-to-Head: Abiomed vs. STERIS
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться